title: Association of serum EPCA-2 level with prostate cancer in Chinese Han population.
abstract: BACKGROUND
  Early prostate cancer antigen 2 (EPCA-2), a kind of nuclear matrix protein, may relate to prostate cancer. However, the association of EPCA-2 level in serum with prostate diseases has not been clarified in Chinese Han population.
  
  
  METHODS
  EPCA-2 and prostate-specific antigen (PSA) levels in serum were detected by enzyme linked immunosorbent assay in 116 patients with prostate cancer (PCa), 342 patients with benign prostatic hyperplasia (BPH), and 174 healthy controls (Control) in Chinese population. Associations of serum EPCA-2 and PSA level with prostate diseases were analyzed by ANOVA. Comparison of diagnostic effect for prostate cancer between EPCA-2 and PSA was evaluated by Receiver Operator Curve, Chi-square test, and others.
  
  
  RESULTS
  Serum EPCA-2 and PSA levels in PCa group were significantly higher than BPH and Control group (EPCA-2: F=200.05, P<0.01; PSA: F=210.65, P<0.01). However, EPCA-2 levels in the prostate cancers with different pathological grade were no significant difference. Furthermore, for detection of prostate cancer, EPCA-2 had a sensitivity of 81.9% and a specificity of 87.6%.
  
  
  CONCLUSIONS
  Serum EPCA-2 could be used as a potential serological marker to diagnose prostate cancer in Chinese Han population, which was more specific than PSA and did not associate with pathological grades of prostate cancer.
authors.affiliation: Department of Urology I, Xinxiang Central Hospital Xinxiang, Henan, China ; Department of Urology, Chinese PLA General Hospital, Medical School of Chinese PLA Beijing, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Urology II, Xinxiang Central Hospital Xinxiang, Henan, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Ma
authors.affiliation: Department of Urology I, Xinxiang Central Hospital Xinxiang, Henan, China.
authors.forename: Xinli
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Inspection, Xinxiang Central Hospital Xinxiang, Henan, China.
authors.forename: Bing
authors.initials: B
authors.lastname: Li
authors.affiliation: Department of Inspection, Xinxiang Central Hospital Xinxiang, Henan, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Guo
authors.affiliation: Department of Urology I, Xinxiang Central Hospital Xinxiang, Henan, China.
authors.forename: Qingdong
authors.initials: Q
authors.lastname: Qiao
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D044466:Asian People; D014408:Biomarkers, Tumor / Q000097:blood; D002681:China; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000473:pathology; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D012680:Sensitivity and Specificity
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C542166:early prostate cancer antigen-2, human; D017430:Prostate-Specific Antigen
keywords: Chinese; EPCA-2; PSA; prostate cancer; serum marker